// App-Quantinova.ai

3022 : BAY 1143572, a first-in-class, highly selective, potent and orally available inhibitor of PTEFb/CDK9 currently in Phase I, shows convincing anti-tumor activity in preclinical models of acute myeloid leukemia (AML)

Researchers

Presenter

  • Arne Scholz

Principal Investigators

  • Thomas Oellerich

  • Akhtar Hussain

  • Sarah Lindner

  • Ulrich Luecking

  • Annette O. Walter

  • Peter Ellinghaus

  • Ray Valencia

  • Franz von Nussbaum

  • Dominik Mumberg

  • Michael Brands

  • Stuart Ince

  • Hubert Serve

  • Karl Ziegelbauer

Medical Centers

  • Bayer Pharma AG, Berlin, Germany

  • Department of Medicine, Hematology/Oncology, Goethe University of Frankfurt, Frankfurt, Germany

Locations

  • Germany

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

  • Solid malignancies

Biomarkers

  • Myeloid Cell Leukemia 1

Drug/Treatment

  • BAY-1143572

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved